The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Lot's of tangential thought processes going on, but it was actually stated in the RNS, that there would be further updates to be given at AACR:
"We are now in a very strong position to deliver significant clinical and commercial milestones relating to AVA6000 and the wider pre|CISION? platform, and we are looking forward to providing a further detailed update on the clinical trial at the American Association for Cancer Research meeting in April."
Since the drop to the 50's, 76m shares have been soaked up at this price, on top of the placing number. That's a pretty decent support structure, and don't see how/why it could push below 50 without it getting snapped up.
This whole business of could or couldn't they have raised 25m from PI's, I have little doubt it would have been considered, and advise sought on whether they could have pulled it off. Would the city boys have been tipped off and ruined the party? The result may have been a crashed share price and a failed PI raise. Just don't know. At the end of it all, the dilution is just 20%, not 50%, as it appears from the share price, and the cash gives avacta enough runway to reach some serious value events.
That's part of the excitement of this trial. By targeting high fap expressing tumours the net is cast very wide indeed, but that requires vast resources to cover, and for each indication there will be tuning to be done. The safety profile to date also allows for a wide range of experimental dosing regimens which would ordinarily be limited by toxicity. The two combined means the market could be very large indeed, but requires time and resources to match.
Oh for sure that is the case. That is the pharmacokinetics aspect of all of this. Some tumours won't express high fap, others are in low blood zones, such as bone cancers. Part of the challenge of oncologists has always been finding the right treatment for a tumour.
They went into the levels in the science day. You should also watch that again. The biopsies were optional, so not all 40 patients gave permission, and others are still alive and receiving treatment! Of those that were obtained, they all demonstrated doxorubicin had been released.
Thorn please go and watch that link between the timeframes outlined. This part of the trial has unequivocally answered the questions:
1. Is AVA6000 safer than straight dox? Yes
2. Is AVA6000 cleaved in the tumour in therapeutic levels? Yes.
3. Does AVA6000 allow for more frequent and extended dosing? Yes, to the latter, in theory yes to the former, but we’ll know the outcome of that in terms of safety and efficacy shortly.
Thanks smee, always worth revisiting that presentation.
Thorn, Touk, Wyndrum - you all seem to have reservations and theories around the mechanism of action of AVA6000, on efficacy, dox concentrations, excretion rates etc. You can get answers to these if you watch from 16-39m, where this is all explained by CC.
Sorry to break this to you Timster, but wyndrum with all his hot air and contradiction still manages to at least provide more worth to this board than yourself. Tell us all, are you paid to pour cold water on every single post, or self-appointed?
We were discussing the link between SP and whether this is a reflection of the science or not. You decided not to answer the points I put to you in last nights post, so perhaps you don't quite grasp them, or you prefer not to.
If it's easier, then just go with the opinion of simple fund managers, their job is to make money after all. Oliver Brown of RC Brown's fund had this wonderfully insightful observation. He said, at 50p the risk reward is in our favour, which is why we found this attractive to participate at this price.